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Abstract
Painful stimuli during neonatal stage may affect brain development and contribute to abnormal behaviors in
adulthood. Very few specific therapies are available for this developmental disorder. A better understanding of the
mechanisms and consequences of painful stimuli during the neonatal period is essential for the development of
effective therapies. In this study, we examined brain reactions in a neonatal rat model of peripheral inflammatory
pain. We focused on the inflammatory insult-induced brain responses and delayed changes in behavior and pain
sensation. Postnatal day 3 pups received formalin injections into the paws once a day for 3 days. The insult
induced dysregulation of several inflammatory factors in the brain and caused selective neuronal cell death in the
cortex, hippocampus and hypothalamus. On postnatal day 21, rats that received the inflammatory nociceptive
insult exhibited increased local cerebral blood flow in the somatosensory cortex, hyperalgesia, and decreased
exploratory behaviors. Based on these observations, we tested recombinant human erythropoietin (rhEPO) as a
potential treatment to prevent the inflammatory pain-induced changes. rhEPO treatment (5,000 U/kg/day, i.p.),
coupled to formalin injections, ameliorated neuronal cell death and normalized the inflammatory response. Rats
that received formalin plus rhEPO exhibited normal levels of cerebral blood flow, pain sensitivity and exploratory
behavior. Treatment with rhEPO also restored normal brain and body weights that were reduced in the formalin
group. These data suggest that severe inflammatory pain has adverse effects on brain development and rhEPO
may be a possible therapy for the prevention and treatment of this developmental disorder.
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Introduction
Clinical and basic studies have shown that early expo-
sure to pain, particularly during periods of high brain
plasticity and vulnerability in the neonates, alters normal
neuronal connections and causes anatomic, electrophy-
siological and molecular changes that manifest as neuro-
logic deficits in adolescence and adulthood [1,2]. Adults
who were prematurely born are particularly more likely
to suffer from altered states of pain sensitivity, learning
and psychiatric disorders, hyperactivity and attention
deficit disorders [3]. A potential mechanism for the
behavioral alterations may be related to the observation
that repetitive pain induces neuronal activation and
widespread neuronal death in the brain [4]. The benefits
of treating the neuronal cell loss in preventing the beha-
vioral deficits, however, have not been studied.
Premature infants are babies born before completing
37 weeks of pregnancy. About 50,000 premature infants
are born every year in the United States [5] reflecting a
20% increase in the last two decades [6]. Prematurity
exposes infants to an environment that their bodies are
not able to cope with yet. In the Neonatal Intensive
Care Unit (NICU), premature infants undergo several
tissue damaging procedures that induce extensive pain.
For years, it was believed that infants do not feel pain as
adults do. However, it has been recently shown that
newborn infants do experience pain and, in fact, they
may be even more sensitive than adults because they
lack fully developed descending inhibitory tracts in the
brainstem and spinal cord [7]. Zhuo and Gebhart
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showed that neonatal capsaicin treatment had significant
effects on the bulbospinal systems important for the
modulation of spinal nociceptive transmission. Specifi-
cally, capsaicin treatment of neonates leads to a reduc-
tion in inhibitory and an increase in facilitatory
regulation on spinal nociception descending from the
caudal brainstem [1]. In addition, sensory fibers relaying
pain and mechanical information initially overlap during
development making mechanical stimulation in neonates
painful [8]. Despite the individual, social and economic
burden of prematurity, relatively little effort has been
invested to investigate the possibility that painful experi-
ences during the neonatal period may have lasting
impacts on brain development and behavioral complica-
tions in children and adults. Moreover, there are no
FDA approved drugs specifically designed to ameliorate
the consequences of prematurity or mitigate the long-
term effects of the resulting developmental disorder.
Some investigators suggested the use of the analgesic
drug ketamine to reduce cell death in the brain and
reverse the behavioral sequel of early repetitive pain [4].
Arguably, ketamine itself can cause neurodegeneration
in immature cells of the developing brain especially at
high dosages [9]. Several other pharmacological drugs
have been tested for reducing the impact of pain in neo-
nates. While topical anesthetics have failed clinical trials
[10-12], the use of opioids is not favored because of its
adverse effects on neuronal development [13]. Several
other non-pharmacological interventions have been
explored for the same purpose with variable efficacies
such as nutritional support [14] and maternal holding
and skin-to-skin care [15-17].
Erythropoietin is a glycoprotein produced by the kid-
ney under conditions of systemic hypoxia to stimulate
erythropoiesis [18]. Recombinant human erythropoietin
(rhEPO) has been used for the treatment of anemia,
myelodysplasia and some other illnesses [19,20]. Because
of its multi-level protective effects and its safety profile,
rhEPO has been tested in CNS disorders as well. For
example, rhEPO showed neuroprotective effects after
cerebral ischemia [21]. Administration of rhEPO after
ischemic stroke reduces infarct volume [22], apoptotic
cell death [23], and inflammation [24]. rhEPO enhances
neurogenesis and angiogenesis and improves functional
recovery following ischemic stroke [25]. rhEPO has been
also found to be safe and efficacious in a preliminary
clinical trial of human stroke patients [26]. Interestingly,
rhEPO reduces pain after peripheral nerve injury [27]
and in rheumatoid arthritis [28] most likely due to its
anti-inflammatory action.
Given the prominent and proven therapeutic effects of
rhEPO in the CNS, we hypothesized that the neuropro-
tective and anti-inflammatory actions of rhEPO could
be used to reduce inflammatory pain-associated cell
death in the brain and ameliorate the long-term beha-
vioral consequences of repetitive painful stimuli during
the early postnatal days.
Materials and methods
Chemicals
Formalin was purchased from VWR international (West
Chester, PA). Recombinant human erythropoietin
(rhEPO) was purchased from Amgen Biologicals (Thou-
sand Oaks, CA).
Animals and inflammatory pain model
The animals were kept under standardized temperature,
humidity, and lighting conditions, with free access to
water and food. Postnatal day 3 (P3) rat pups were sub-
jected to 5% formalin (10 μl) subcutaneous (s.c.) injections
into the four paws. rhEPO was administered 30 min before
formalin injection in the EPO treated group. Some animals
were injected once and sacrificed 4 or 12 hours later; while
others were injected for three consecutive days and sacri-
ficed on postnatal day 6 or 21 (P6 or P21). Pups were
returned to their mothers immediately after each injection.
The health condition of each pup was monitored each day
for feeding behaviors and signs of feet swelling, skin infec-
tion, and pain development. Animals with skin infection,
excessive swelling and pain were sacrificed without further
testing. Mild paw swelling and skin redness recovered fully
within 3 days after injection. After sacrifice, brain and
dorsal root ganglia (DRG) tissues were collected for
immunostaining and/or Western blot analysis. All studies
were approved by the Institutional Animal Care and Use
Committee (IACUC).
Histochemical staining
Under isofluorane anesthesia, animals were transcar-
dially perfused with 10% formalin. Brain coronal sec-
tions were sliced at 20 μm thickness using a cryostat
vibratome (Ultapro 5000, St louis, MO, USA) and were
mounted on gelatin coated slides. Fluoro-Jade C (FJC)
staining [29], a valid and reliable stain for degenerating
neurons, was conducted as reported earlier with some
modifications. In brief, tissue sections were dried for 15
minutes. After three PBS washes, the sections were
immersed in 0.8% NaOH in 80% ethanol followed by
70% ethanol and water washes, respectively. The sec-
tions were then immersed in 0.06% KMnO4, followed by
0.0002% FJC. The section were thereafter washed, dried
and mounted for microscopy using the FITC channel
on an upright Olympus fluorescence microscope.
Terminal deoxynucleotidyl transferase Biotin-dUPT nick
end (TUNEL) staining
TUNEL staining was performed using a commercial kit
(DeadEnd™ Fluorometric TUNEL system, Promega,
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Madison, WI, USA) to label dying and dead cells in the
brain. The instructions were followed as given. In brief,
brain sections were placed in equilibration buffer and
incubated with nucleotide mix and rTdT enzyme at 37°
C for 1 hr. The reaction was stopped with 2 × SSC.
Results were visualized using the FITC channel on an
upright Olympus fluorescence microscope.
Cell counting
Cell count was performed following the principles of
design based stereology. Systematic random sampling
was employed to ensure accurate and non-redundant
cell counting [30]. Every section under analysis was at
least a 100 μm away from the next. A total of 6 20-μm
thick sections spanning the entire regions of interest
were randomly selected for cell counting from each ani-
mal. Counting was performed on 6 non-overlapping
randomly selected 20 × fields per section. Sections from
different animals represent the same area in the anterior
posterior direction.
Western blot assays
Brain tissue samples were collected, proteins were
extracted with lysis buffer, and protein concentration was
measured with a BCA assay (Pierce, Rock Ford, IL, USA).
30 μg protein samples were electrophoresed on 6 to 15%
gradient gels in the presence of sodium dodecyl sulfate-
polyacrylamide in a Hoefer Mini-Gel system (Amersham
Biosciences, Piscataway, NJ, USA) and transferred in the
Hoefer Transfer Tank (Amersham Biosciences, Piscat-
away, NJ, USA) to a polyvinylidene difluoride membrane
(BioRad, Hercules, CA, USA). Membranes were blocked
in 7% milk (Tris-buffered saline containing 0.1% Tween-
20, pH 7.6%, 7% milk) at room temperature for 1 h and
incubated overnight at 4°C with rabbit polyclonal anti-
caspase-3 (1:500, Cell Signaling, Boston, MA) and rabbit
anti-apoptosis inducing factor AIF (1:1000, Cell Signal-
ing, Boston, MA) antibodies. Mouse anti-actin antibody
(1:5000, Sigma, St Louis, MO, USA) was used to detect
b-actin, the protein loading control. The blots were
washed in 0.5% Tris-buffered saline containing 0.1%
Tween-20 and incubated with alkaline phosphatase con-
jugated anti-rabbit or anti-mouse (1:2000, Promega,
Madison, WI, USA) antibodies for 2 hrs at room tem-
perature. Finally, membranes were washed with Tris-buf-
fered saline containing 0.1% Tween-20 followed by three
washes with Tris-buffered saline. The signal was detected
by the addition of bromo-chloro-indolyl phosphate/nitro
blue tetrazolium (BCIP/NBT) solution (Sigma, St Louis,
MO, USA), and quantified and analyzed by the imaging
software Photoshop Professional (Adobes Photoshop CS
8.0, San Jose, CA, USA). This whole procedure was
repeated three times with new samples collected from
different animals.
Quantitative real-time polymerase chain reaction (qRT-
PCR)
Total RNA was extracted from the somatosensory cor-
tex (4 and 12 hours after single injection and after 3
days’ consecutive injections at P6 and P21) and dorsal
root ganglia (12 hours after single injection) using the
TRIzol reagent (Invitrogen Inc, Carlsbad, CA). Reverse
transcription was performed with 2 μg total RNA using
the High Capacity cDNA Reverse Transcription kit
(Applied Biosystems, CA, USA). SYBR green qRT-PCR
was used to assess the relative levels of our target genes
using the Applied Biosystems StepOnePlus machine.
The primers used were: TNF-a: F-primer: CCCCAT-
TACTCTGACCCCTT; R-primer: TTGTTGGAAA
TTCTGAGCCC; Il-6: F-primer: GCCCTTCAGGAA-
CAGCTATG; R-primer: CCGGACTTGTGAAG-
TAGGGA; Il-1b: F-primer: CATCTTTGAAGAAG
AGCCCG; R-primer: AGCTTTCAGCTCACATGGGT;
substance P (SP): F-primer: TGACCAAATCAAG-
GAGGCAAT; R-primer: GGGTCTTCGGGCGATTCT;
Calcitonin gene related peptide (CGRP): F-primer:
AAGTTCTCCCCTTTCCTGGTTGTCA; R-primer:
TGGTGGGCACAAAGTTGTCCTTCAC;
Fold change was calculated by the delta (delta Ct)
method using the 18S ribosomal RNA subunit amplifi-
cation as the internal control. All experiments were
repeated three times using distinct animals by two dif-
ferent investigators.
Behavioral tests
To evaluate the behavioral changes in the experimental
and control groups, we utilized the following behavioral
tests.
Hot-Plate test
Pain sensitivity was measured on a hot plate at 55 +/- 1°C.
Latency was measured as the time for the rat to jump,
shake its limb or lick its paw with a maximum allowed
time of 30 sec. Latency was measured as an average of
three readings separated by at least 15 minutes.
Tail-flick test
The tail-flick test was performed using 55°C water as
the nociceptive stimulus. The latency to remove the tail
was measured three times separated by at least 15
minutes.
Defensive-withdrawal test
Animals were tested for exploratory behavior using the
defensive withdrawal test for 10 min on postnatal day
21. During the test, the animals were placed in a dark
chamber (10 × 15 × 10 cm high) placed along the wall
of a large box (50 × 40 × 50 cm high). Animals were
habituated to the open field 24 hours prior to behavioral
testing by allowing them to explore the open field for 15
min without access to the defensive withdrawal cham-
ber. The latency was measured as the time it takes the
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animal to place its four paws outside the small chamber.
The experiment was performed by two separate indivi-
duals blinded to the identity of the groups.
Locomotor function tests
Motor function was assessed by the Rota-rod and open
field tests. In the Rota-rod test, we measured the latency
to fall off the rotating rod with a maximum cut-off time
of 6 min. Averages of three trials, separated by at least
15 min, were calculated. In the open-field test, rats were
allowed to freely move in an open field container (50
cm × 40 cm × 50 cm high) during the dark cycle. The
container was divided into 16 equal squares and the
number of line crossings by each animal was calculated
for 5 min.
Cerebral blood flow measurement
Cerebral blood flow was measured using laser-Doppler
flowmetry (PeriFlux System 5000 - PF5010 LDPM unit,
Perimed, Stockholm, Sweden). The tip of a flexible 0.5
fiber optic probe was pointed over the somatosensory
cortex. Measurements were taken before and after the
last injection of formalin on postnatal day 5 during the
third injection session. The final value is the ratio of
blood flow after to before injections and it is an average
of five consecutive readings.
Statistical analysis
All analyses were performed using GraphPad Prism 4.0
statistical software (GraphPad Software, Inc., La Jolla,
CA). Multiple comparisons were performed by one- or
two-way analysis of variance (ANOVA) followed by
Bonferroni’s post hoc analysis. Single comparisons were
performed using Student’s t-test. Changes were consid-
ered significant if the p-value was less than 0.05. Mean
values were reported with the standard error of the
mean (SEM).
Results
Formalin-induced peripheral inflammatory pain model in
neonatal rats
The subcutaneous formalin administration into the paws
of rodents is a well established nociceptive insult used in
peripheral inflammatory pain models [31,32]. P3 neona-
tal rats were randomized to four groups: saline injection
controls, rhEPO injection controls, formalin injection
group and formalin coupled to intraperitoneal (i.p.)
injection of rhEPO (5,000 U/kg). It is estimated that the
rat brain at postnatal days 1-10 is equivalent to a third
trimester human brain and that rat neurodevelopment
at postnatal day 7 is equivalent to that of the human
brain at birth [33,34]. The postnatal day 3 was selected
to mimic premature birth in humans. rhEPO was admi-
nistered 30 min before each formalin injection in the
formalin plus EPO treatment group. Formalin (5%, 10
μl) was subcutaneously injected into the four paws,
starting on P3. Animals sacrificed at 4 and 12 hours
received only one treatment with saline control, rhEPO
alone, formalin alone or formalin plus rhEPO, respec-
tively. Animals sacrificed at P6 (72 hrs) and P21
received injections from P3 to P5 once a day in each
paw. Rat pups receiving formalin injections showed skin
redness and moderate swelling at injection sites. These
changes fully reversed in 3 days. We regard the
employed formalin model as a severe and subacute
inflammatory pain model, suitable for generating notice-
able short- and long-term alterations.
As a control study for identifying the effect of rhEPO
on cytokine expression and animal behavior, we injected
rhEPO alone in P3 neonatal rats and inspected cytokine
expression 12 hrs later, and cytokine expression and
behavior at P21. Injection of rhEPO into P3 neonatal
rats did not affect IL-6, TNF-a and IL-1b transcription
levels 12 hrs later (Figure 1A to 1C). Moreover, rhEPO,
injected three times in neonatal rats at P3, P4 and P5,
did not affect transcription of inflammatory cytokines
(IL-6, TNF-a and IL-1b) examined at P21 (Figure 1D to
1F). In addition, the behavior of P21 juvenile rats
(injected with rhEPO at P3, P4 and P5) was not affected
in the defensive-withdrawal, hot-plate or Rota-rod tests
(Figure 1G to 1I).
rhEPO treatment reduced inflammatory pain-induced cell
death in the neonatal brain
TUNEL staining was used to investigate the extent of
cell death in the brain. TUNEL identifies fragmented
DNA in all types of dying cells [35,36]. In addition, we
used Fluoro-Jade C (FJC) to specifically identify dying
neurons [29]. The analysis of data from TUNEL staining
after 3 sessions of formalin injection (72 hrs) revealed
that the peripheral inflammatory nociceptive insult
caused widespread cell death in the cortex and hypotha-
lamus (Figure 2A, C and 2E), whereas rhEPO co-treat-
ment effectively reduced cell death in these areas
(Figure 2B, D, and 2F). Counting of TUNEL-positive
cells in the cortex, hippocampus and hypothalamus
showed a significant effect of rhEPO in reducing cell
death after repeated formalin injections (Figure 3E). In
the hippocampus and hypothalamus, rhEPO treatment
showed significant protection. TUNEL positive cells
were reduced from 303 ± 44/field in the formalin alone
rats to 227 ± 59/field, and from 278 ± 50/field to 224 ±
32/field in these two regions, respectively (n = 6 and p
< 0.05 in both analyses). The number of TUNEL-posi-
tive cells in the cortex of rhEPO-treated rats was 145 ±
24 as compared to 170 ± 37/field in the formalin alone
group (however, p > 0.05, n = 6 rats in each group).
The more specific neuronal stain FJC further verified
that treatment with rhEPO dramatically reduced
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neuronal cell death in the cortex, hippocampus (Figure
2G to 2I) and hypothalamus after a single (4 and 12
hrs) or 3 formalin injections (72 hrs) (Figure 3A to 3C).
For example, 12 hrs after a single injection, rhEPO
reduced FJC-positive cells from 408 ± 41/field to 148 ±
12/field in the cortex, from 1136 ± 71/field to 368 ± 23/
field in the hippocampus, and from 548 ± 50/field to
182 ± 21/field in the hypothalamus (p < 0.05 vs. saline
control in all three comparisons; n = 6 in each group)
(Figure 3B). At age P21, the number of dying neurons
was similar in the control, formalin injected and EPO
treated groups and they were significantly lower than
the earlier time points (Figure 3D).
rhEPO reduced formalin-induced apoptotic cell death in
the neonatal brain
Immature neurons are more vulnerable to apoptotic
insults [37]. We tested the hypothesis that formalin
Figure 1 Effect of rhEPO on cytokine expression and behavioral activities. Control tests were performed to evaluate whether rhEPO
injection affect inflammatory cytokine expression in neonatal rats or behavior in juvenile rats. A - C: The mRNA levels of IL-6, TNF-a and IL-1b in
the somatosensory cortex 12 hrs after a single injection of rhEPO (5000 U/kg) in P3 neonatal rats. D - F: The mRNA levels of IL-6, TNF-a and IL-
1b in the somatosensory cortex on postnatal day 21 after 3 injection sessions of rhEPO (5000 U/kg) in P3-P5 neonatal rats. G - I: rhEPO did not
influence the behavior of juvenile rats that were injected three times with rhEPO at P3, P4 and P5. Saline injected controls and rhEPO injected
animals performed similarly in the defensive-withdrawal (G), hot-plate (H) and the Rota-rod (I) tests (n = 4 for each group).
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Figure 2 Effect of rhEPO on inflammatory pain-induced cell death. rhEPO reduced cell death in the cortex, hypothalamus and hippocampus
after 3 formalin injection sessions (72 hrs). A - F: Immunofluorescent images of TUNEL-positive cells (arrow) in the cortex (A and B) and the
hypothalamus (C and D). E and F are magnified selected areas in C and D, respectively. The inset in E is a further enlarged (40×) image of
the selected area (Blue: Hoechst, green: TUNEL). G - I: Immunofluorescent images of fluoro-Jade C positive neurons (arrowheads) in the
hippocampus after 3 repetitive saline (G), formalin (H) or formalin plus rhEPO injection (I) sessions (green: FJC-positive cell). Bar = 100 μm for
A to D, 50 μm for E and F, and 100 μm for G to I.
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Figure 3 Neuroprotective effect of rhEPO. rhEPO reduced cell death after repetitive formalin injections in the cortex, hypothalamus and
hippocampus after repetitive formalin injections. A - D: Quantifications of the number of fluoro-Jade C positive neurons in the cortex,
hippocampus and hypothalamus 4 (A) and 12 hrs (B) after a single injection or after 3 injections at P6 (C) and P21 (D). E: Quantification of
TUNEL-positive cells in the cortex, hippocampus and hypothalamus after 3 injection sessions (n = 6 in each group). *. p < 0.05 compared to
saline group; #. p < 0.05 compared to formalin group. F: Western blot analysis of somatosensory cortex proteins from saline, formalin or formalin
plus rhEPO groups. Cleaved caspase-3 was measured in total lysates and Apoptosis Inducing Factor (AIF) was inspected in the cytosolic extracts
72 hrs after 3 injections sessions. b-actin was used as the loading control. N = 4 for caspase-3 and n = 6 for AIF. *. p < 0.05 compared to saline
group; #. p < 0.05 compared to formalin group.
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injection triggers the activation of apoptotic mech-
anisms in the neonatal brain. To check for this possi-
bility, we performed Western blot analysis on
somatosensory cortical tissues collected after 3 forma-
lin injections in 3 days and probed for the levels of
caspase-3 and apoptosis-inducing factor (AIF). Forma-
lin injections led to a significant rise in the levels of
cleaved caspase-3 compared to saline group (1.48 ±
0.13 vs. 0.97 ± 0.17 folds; p < 0.05), whereas rhEPO
co-treatment strongly prevented caspase-3 activation
(0.84 ± 0.16 vs. 1.48 ± 0.13 folds; p < 0.05) (Figure 3F).
The formalin insult did not change the cytosolic levels
of AIF, which represents the caspase-independent
apoptosis [38].
rhEPO modified the inflammatory response by regulating
cytokine levels
To further characterize the mechanisms by which for-
malin caused widespread cell death in the brain, we
aimed to identify the transcriptional levels of some
major inflammatory cytokines involved in the patho-
genesis of inflammatory pain. To measure transcrip-
tion, we used real-time PCR to follow mRNA
production of IL-6, IL-1b, and TNF-a in the somato-
sensory cortex and substance P (SP) and calcitonin-
gene-related peptide (CGRP) in the dorsal root ganglia
(DRG) corresponding to the upper and lower limbs. In
the somatosensory cortex, formalin injection signifi-
cantly increased Il-6 at the 4 hrs time point (19.0 ± 3.0
folds increase; p < 0.05) (Figure 4E). TNF-a level was
significantly enhanced at the 4 hr (11.1 ± 2.7 folds)
and 72 hr (13.0 ± 3.5 folds) time points (p < 0.05 in
both comparisons) (Figure 4I and 4K). IL-1b level
increased 2.3 ± 0.5 folds (p < 0.05 compared to con-
trols) (Figure 4B) at the 12 hrs time point. On the
other hand, formalin injection reduced IL-1b levels at
4 and 72 hrs after injection (Figure 4A and 4C).
rhEPO treatment effectively prevented the increases in
IL-6 and TNF-a levels at 4 and 72 hrs, respectively
(Figure 4E and 4K). However, rhEPO did not reduce
the levels of TNF-a 4 hrs after formalin injection.
TNF-a transcription level was still high at this early
time point (Figure 4I). In addition, there was no signif-
icant difference in the transcriptional levels of IL-1b,
IL-6, or TNF-a when measured at age P21 after 3
injection sessions (Figure 4D, H and 4L). Moreover, we
detected a strong trend of decreased SP level (0.31 ±
0.20 folds vs. the control; but p > 0.05) and a
decreased CGRP level (0.09 ± 0.08 folds vs. the con-
trol; p < 0.05) 12 hrs after a single formalin injection.
Treatment with rhEPO significantly increased the
mRNA expression of SP (2.2 ± 0.2 folds vs. formalin
alone; p < 0.05) and CGRP (1.9 ± 0.4 folds vs. formalin
alone; p < 0.05) (Figure 4M and 4N).
rhEPO treatment prevented abnormal pain sensitivities
A major complication of early exposure to painful
experiences is altered pain sensation in adult life [39,3].
This fact prompted us to test pain sensitivities in 21-day
old juvenile rats after they have received three injection
sessions of saline, formalin alone or formalin plus
rhEPO in infancy (P3 to P5). We noticed that rats
which received repetitive formalin injections had
reduced pain thresholds in the hot-plate test (9.9 ± 0.9
sec vs. 17.1 ± 2.8 sec; p < 0.05). Interestingly, there was
no difference in their pain thresholds in the tail-flick
test (1.5 ± 0.2 sec vs. 1.5 ± 0.3 sec; p > 0.05) (Figure 5A
and 5B), suggesting that the peripheral inflammatory sti-
muli selectively affect supra-spinal but not spinal pain
pathways. Treatment with rhEPO prevented the hyperal-
gesia in the hot-plate test (Figure 5A), which is consis-
tent with the rhEPO effect in L5 spinal nerve
transection neuropathic pain model [40].
Effect of rhEPO on increases in cerebral blood flow
induced by inflammatory pain
To check if the altered pain sensitivity is associated with
increased brain activity during the painful stimuli, we
measured local cerebral blood flow (LCBF) in the brain
5 min before and immediately after formalin injection
on the third and last day of injections in animals that
have received three injection sessions (postnatal day 5).
Formalin injection significantly increased blood flow in
the right somatosensory cortex; whereas treatment with
rhEPO restored normal flow (Figure 5C and 5D). Same
results were obtained from the left hemispheres (Figure
5E). These data suggested that peripheral inflammatory
pain causes a state of hypersensitivity/hyperactivity in
the brain and rhEPO was able to restore normal brain
activity levels upon the painful stimuli.
rhEPO treatment improved exploratory behavior on
defensive-withdrawal test
Behavioral disturbances and psychiatric disorders are
major complications that stem from early painful
experiences. Defensive-withdrawal test evaluates
exploratory behavior in rats. After 3 sessions of forma-
lin injections in the neonatal period, we tested explora-
tory behavior in the juvenile 21-day old rats. Formalin
injections increased the time spent in the dark cham-
ber (456 ± 95 sec vs. 10 ± 3 sec in control rats; p <
0.05). rhEPO treatment corrected this abnormal beha-
vior back to the normal level (17 ± 8 sec; p > 0.05
compared with controls) (Figure 6A). To rule out the
possibility that the formalin insult impaired locomotor
functions, we tested locomotion using the Rota-rod
and open field tests in the P21 rats. There were no sta-
tistically significant differences on either test among
the three groups (Figure 6B and 6C).
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rhEPO treatment helped retain brain and body weights
In the long-term experiments, we tested the effect of
formalin injections on brain and body weights in the
P21 rats of the three experimental groups. Rats that
received formalin injections during their neonatal period
showed significantly less body (25.8 ± 1.0 g vs. 39.7 ±
0.6 g; p < 0.05) and brain (1.1 ± 0.02 g vs. 1.3 ± 0.03 g,
p < 0.05) weights compared to the control group. These
decreases in body and brain weights were not seen in
rats that also received rhEPO. Their body and brain
weights remained within the normal ranges (Figure 7A
and 7B).
Discussion
The present investigation reveals that severe inflamma-
tory nociceptive insults occurring in neonatal rats cause
brain cell death and have significant adverse impacts on
brain development and behavioral activities in adoles-
cence. Specifically, rats that suffer painful inflammatory
nociception in infancy developed hyperalgesia and
abnormal stress behaviors. We show for the first time
that rhEPO is an effective drug that antagonizes the
inflammatory response and brain damage caused by
inflammatory pain. rhEPO treatment prevents the devel-
opment of hyperalgesia and corrects the stressful
Figure 4 Effects of rhEPO on expression of inflammatory factors. Real time PCR measurements of inflammatory factors in somatosensory
cortex or DRG from control and experimental rats. A - D: The mRNA levels of IL-1b in the somatosensory cortex 4 and 12 hrs after a single
injection or after 3 injection sessions (72 hrs and P21) of saline, formalin or formalin plus rhEPO groups. E - H: The mRNA levels of IL-6 in the
somatosensory cortex 4 and 12 hrs after a single injection or after 3 injection sessions (72 hrs and P21) of saline, formalin or formalin plus rhEPO
groups. I - L: TNF-a mRNA levels in the somatosensory cortex 4 and 12 hrs after a single injection or after 3 injection sessions (72 hrs and P21).
M and N: The mRNA levels of CGRP (J) and substance P (SP) in DRG neurons 12 hrs after a single injection. All results are expressed as fold
changes compared to the control. 18S rRNA was used as an internal control. n = 6 in each group; *. p < 0.05 compared to saline group; #. p <
0.05 compared to formalin group.
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Figure 5 Effect of rhEPO on pain sensitivity and cerebral blood flow of formalin-injected rats. Rats were subjected to pain sensitivity hot
plate and tail flick tests and cerebral blood flow was measured using a laser Doppler scanner. A and B: Measurements of pain latencies on hot-
plate (A) and tail-flick (B) tests in 21 day old juvenile rats after different treatments during infancy (P3 to P5). rhEPO restores normal pain
sensitivity after formalin injections. C: Representative laser Doppler graphs of blood flow levels in the right somatosensory cortex of P5 rats after
the third injection of formalin or formalin plus rhEPO. The calibration bar on the right shows relative levels of flow. D and E: The ratio of blood
flow after/before injections from experiments in C, in the right (D) and left (E) hemispheres. The values are averaged from five consecutive
readings. N = 7 in pain tests and n = 6 in blood flow measurements; *. p < 0.05 compared to saline group; #. p < 0.05 compared to formalin
group.
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behavior chronically developed in these young animals.
Moreover, treatment with rhEPO maintains normal
brain and body weights that were reduced in animals
suffering repetitive inflammatory stimuli.
Contrary to what was previously believed neonates can
feel pain and, in many cases, pain is more intense than
in adults due to the underdeveloped inhibitory mechan-
isms in the brain and spinal cord [1,7,8]. In clinical
cases, painful stimuli and inflammatory pain occur in
human infants. For example, prematurely born infants
in the intensive care unit are subjected to painful proce-
dures including, but are not limited to, heel sticks,
endotracheal intubations, respiratory and gastric suc-
tioning and catheter insertions [41]. It is noticed that
these infants may develop behavioral and emotional pro-
blems in childhood, altered pain responses, depression
and other psychiatric disturbances in adulthood [2]. The
cellular, molecular and pathological mechanisms of this
disorder are not well understood. Previous studies
showed that full term neonates exposed to painful sti-
muli at birth develop acute adverse effects that last only
for hours and are not chronic like those seen in prema-
ture babies [42,43]. It is likely that the data from the
present investigation are more relevant to immature
infants subjected to severe and repetitive inflammatory
pain.
Formalin s.c. injection is used as a model for inflam-
matory pain. Formalin is usually applied as a fixative in
Figure 6 Effect of rhEPO on abnormal exploratory behaviors induced by inflammatory pain. Exploratory behaviors and motor functions
were tested in juvenile rats that were exposed to control or three formalin injections with and without rhEPO in infancy. A: Quantification of the
latency to leave the small chamber in defensive-withdrawal test in 21 day old rats. Rats in the formalin group hesitated to leave the chamber
while rhEPO co-injection prevented this abnormal behavior. B: Rats were placed in an open field and their locomotion was monitored for 5 min.
The numbers of lines rats crossed were counted and there was no difference between groups, suggesting unaffected motor function. C: The
time rats spent on the rotating beam in Rota-rod test, showing no difference between groups. N = 7 in the defensive-withdrawal test and n = 5
in the Rota-rod and open-field tests; *. p < 0.05 compared to saline group; #. p < 0.05 compared to formalin group.
Figure 7 Effect of rhEPO on body and brain weight loss induced by inflammatory pain. Rats that received formalin injections during
infancy underwent body and brain weight loss when growing up to juvenile age. A and B: Measurements of body and brain weights
respectively in 21-day old rats subjected to 3 injections of saline, formalin or formalin plus rhEPO in infancy. Co-injecting rhEPO improved brain
and body weights in these developing animals. N = 8 in each group; *. p < 0.05 compared to saline group; #. p < 0.05 compared to formalin
group.
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immuno-histochemical staining. It fixes tissues by rever-
sibly cross-linking primary amino groups in proteins
with nearby nitrogen atoms. When injected subcuta-
neously, formalin causes extensive firing of primary
afferent nerves such as the C-fibers and widespread sig-
naling activities in the brain and spinal cord [44] result-
ing in a state of repetitive inflammatory pain in animals
[31]. Formalin causes extensive neuronal activity that
lead to glutamate excitotoxicity and increased neuronal
death in the brain [45]. In line with these pathophysiolo-
gical events, we observed high levels of TUNEL and FJC
staining in the cortex, hippocampus and the hypothala-
mus after formalin injection. The cortical regions are
the primary somatosensory and associative sensory
areas, which receive input from the primary afferents
through the thalamus. The hippocampus, on the other
hand, is part of the limbic system and it extensively
receives nociceptive input and mediates a variety of
functions including emotions and behaviors, whereas
the hypothalamus, part of the hypothalamic-pituitary-
adrenal axis, mediates a variety of metabolic, neuroen-
docrine and autonomic activities in response to physio-
logic and pathologic stresses. The roles of these areas in
mediating somatosensory and behavioral functions and
excitotoxicity explain, at least partly, the consequences
of the high cell death levels detected after formalin
injection. A recent study showed that formalin stimula-
tion in neonatal rats causes long-term behavioral
changes, altering exploratory behavior and anxiety levels
in adulthood in a gender (female) specific manner [46].
In that study, a relatively minor insult of single paw for-
malin injection was tested. It will be interesting to see if
gender plays a role in the severe inflammatory pain
model.
Previous work focused on the use of anesthetics and a
few other non-pharmacological interventions to reduce
pain and to prevent the emergence of long-term compli-
cations of early exposure to painful stimuli. However,
given the controversial role and adverse effects of var-
ious anesthetics on the immature brain, for instance
induction of neuronal apoptosis, these treatments have
raised increasing concerns. The present investigation is
the first attempt to utilize a neuroprotective agent,
rhEPO, to prevent the long term complications of early
painful experiences in neonates. rhEPO has been studied
for its safety and efficacy in neonatal brain injury and
for stimulating erythropoiesis in human infants. For
example, extremely low birth weight infants who were
given rhEPO at birth to stimulate erythropoiesis showed
better mental capacities and improved developmental
assessment at the age of 10 [47-49] although other
reports failed to show neurodevelopmental benefits with
rhEPO treatment [50]. It is important to mention, how-
ever, that the neuroprotective effects of rhEPO are
achieved at doses higher than those required for its ery-
thropoietic actions. Nonetheless, human infants did not
develop any of the complications associated with rhEPO
seen in adult patients like hypertension, clotting, poly-
cythemia, and tumor angiogenesis [51,52]. Moreover,
the erythropoietic actions of EPO are beneficial in pre-
term infants who are mostly anemic. We have also
shown that rhEPO injections do not affect cytokine
expression in control animals and that neonatal rhEPO
treatment does not modify behaviors in adolescence.
rhEPO was tested in this investigation as a preventative
and protective treatment for neonates subjected to
severe painful stimuli that cause adverse impacts on
CNS cells and brain development. As the injury is pre-
dicted to occur and as rhEPO is a relatively safe drug,
we believe it is feasible to use rhEPO to co-treat or pre-
treat these neonates. Future studies may be performed
to evaluate the therapeutic benefits of delayed treatment
of rhEPO in older animals.
Subcutaneous formalin injections also cause non-spe-
cific tissue damage and activate other afferents that are
not related to pain processing [53]. We cannot exclude
that rhEPO may show a local anti-inflammatory effect at
the site of formalin injections. We can confirm, how-
ever, that, based on the results of locomotion tests, the
behavioral alterations in the formalin injected rats were
not due to injured paws and impaired locomotor abil-
ities. We have also demonstrated that rhEPO helps to
restore brain and body weights compared to the forma-
lin group. This is a likely indication of complex interact-
ing factors including cell death, cell proliferation/
regeneration and feeding behavior that is linked to the
limbic/hypothalamic interaction.
EPO receptor (EPOR) is abundantly expressed in brain
capillaries, and EPO can cross the blood brain barrier
via endocytosis [21]. In neonatal rat brains, rhEPO
reaches significant levels at 4 hours but peaks later at 10
hours after i.p. injections [54]. This explains the protec-
tive effect of rhEPO in reducing TUNEL and FJC stain-
ing in several brain regions. It is worth to mention that,
when investigated in P21 juvenile rats, we could not
identify any difference in the number of dying neurons
among the three groups. This observation agrees with
the idea that cell death that occurred during early brain
development is critical. rhEPO has anti-apoptotic func-
tions as shown in the reduction of cleaved caspase-3 in
the present study. We additionally revealed that the
inflammatory pain-triggered neuronal apoptosis is cas-
pase-dependent but not AIF-dependent, since this cas-
pase-independent apoptotic factor was not increased by
formalin injections. EPO and EPOR are expressed in
both neurons and glial cells in the central nervous sys-
tem [55]. The binding of EPO to its receptor initiates a
cascade that activates the ERK-1/-2, Akt and JNK-1/-2
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signaling pathways [56]. These pathways eventually
activate factors that inhibit apoptosis, decrease inflam-
mation, increase neurogenesis and angiogenesis. EPO
and EPOR also induce neurogenesis after stroke [57],
early during embryonic development [58] and in vitro
via Jak2/Stat3 and PI3K/AKT pathway activation [59].
We suggest that the therapeutic benefits of rhEPO treat-
ment may be partly attributed to an increase in brain
neurogenesis as well.
Several reports in the literature attribute an anti-
inflammatory action to rhEPO in stroke and endotoxin-
mediated inflammation [24,60]. Both TNF-a and IL-1b
are pro-inflammatory [61] whereas IL-6 can either be
pro- or anti-inflammatory [62]. In the present investiga-
tion, rhEPO reduced IL-1b, IL-6 and TNF-a at many
time points whereas it increased TNF-a at the 4 hrs
time point. It is worth to note that IL-6 significantly
dropped in the formalin group while it increased in the
rhEPO treated group along the 3 time points (from 4 to
72 hrs). TNF-a, on the other hand, significantly
increased in the formalin group while it dropped in the
rhEPO treated group in the same time span. In addition,
it is well established that levels of SP and CGRP drop in
the DRG in models of chronic pain [63] and in the
spinal cord in a neonatal pain model [1]. We demon-
strate, similar to other reports [64], that rhEPO can
reverse signs of central sensitization (restoring normal
levels of SP and CGRP). CGRP expression is regulated
by an upstream MAPK-responsive enhancer element.
Since EPO activates the MAPK signaling cascade, the
increase in CGRP expression can be attributed to EPO-
induced activation of this upstream MAPK-responsive
enhancer [65]. Only mRNA levels were measured in this
investigation, whether the protein levels of these factors
are similarly changed remains to be confirmed.
A recent report shows that rhEPO enhances cognitive
function of memory and learning [66]. This is in line
with our observations in current investigation and, col-
lectively, it is suggested that rhEPO and EPOR may be
explored as targets in a preventive therapy for prema-
ture neonates subjected to repeated painful procedures.
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